News

Article

BostonSight publishes pilot study on PROSE scleral lenses as a drug delivery system for cyclosporine in dry eye treatment

Author(s):

Key Takeaways

  • PROSE treatment uses customized scleral lenses to create a fluid reservoir, promoting corneal healing and comfort.
  • The study tested Cyclosporine 0.05% in the scleral lens reservoir for dry eye disease treatment, showing encouraging results.
SHOW MORE

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

(Image credit: Adobe Stock/marozhkastudio)

(Image credit: Adobe Stock/marozhkastudio)

BostonSight announced the publication of a study titled Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease: A Pilot Study. The study was published in the journal Clinical Ophthalmology

Daniel Brocks, MD, Chief Medical Officer at BostonSight and lead investigator of the study, commented that the publication of this open-label, prospective, non-comparative clinical trial "highlights the investigative approach, concepts, and many important scientific questions regarding the use of PROSE or scleral lenses as a drug delivery device."

PROSE (prosthetic replacement of the ocular surface ecosystem) treatment uses customized scleral lenses to treat patients with corneal irregularities and ocular surface diseases. A scleral lens rests on the sclera and vaults over the cornea, creating a new surface over the damaged cornea. The space between the cornea and the lens is filled with preservative-free saline, creating a fluid reservoir that bathes the cornea continuously, promoting comfort, healing, and relief.1

In this study, BostonSight tested Cyclosporine 0.05% (Restasis; Allergan and Cequa; Sun Pharmaceutical Industries) in the scleral lens reservoir for the treatment of dry eye disease.

“Ultimately, we anticipate that our research in this area will lead to new ocular management strategies that improve ocular health and enhance the lives of our patients,” Brocks said.

The study authors noted that the ophthalmic and optometric community is still in the early stages of investigating the potential use of PROSE or scleral lenses as a drug delivery system for preservative-free ocular medications.1

“This pilot study reports encouraging results in terms of symptom relief and ocular surface tolerability for cyclosporine 0.05% when delivered via a PROSE reservoir,” the authors wrote. “Additionally, early data suggest potential efficacy.”

Overall, the researchers concluded that their findings support further investigation into the safety and efficacy of using the PROSE reservoir as a drug delivery system for Cyclosporine 0.05% in the treatment of dry eye disease.

“Furthermore, this study underscores the importance of a standardized, scientific, stepwise approach to utilizing PROSE or scleral lenses as a drug delivery system,” the authors concluded.

Reference
1. Nakhla MN, Patel R, Crowley E, Li Y, Peiris TB, Brocks D. Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease: A Pilot Study. Clin Ophthalmol. 2024;18:3203-3213
https://doi.org/10.2147/OPTH.S487369

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
© 2025 MJH Life Sciences

All rights reserved.